3Reildy JJ, Gebhardt BM, Zebman HE. The collagen shield. A new vehicle for delivery of cyclosporin A to the eye[J]. Cornea, 1990,9~196.
4Hughes PM, Mitra AK. Effect of acylation on the ocular disposition of acyclovir 2:corneal permeability and anti-HSV1 activity of 2-estttters in rabbit epithelial keratitis[J]. J Ocul Pharmacol,1993,9:299.
5Schaeffer HE, Kmhn DL. Liposomes in topical drug delivery[J].Invest Ophthalmol Vis Sci , 1982,22:220.
6Panzeer EA,Jansons VK. Control of in vitro cytoxicity of positively charged liposomes[J]. J Cancer Res Clin Oncol , 1979,95:29.
7Cohen S, Lobel E, Trevgoda A, et al. A novel in situ-forming ophthalmic drug delivery systems from alginates undergoing gelation in the eye [J] .J Controlled Release, 1997,44(2-3) :201.
8Gurny R, Boye T, lbrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery [J ]. J Controlled Release, 1985,2(3 ): 353.
9Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system [ J ]. J Controlled Release ,2001,73(2) :205.
10Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery [J ]. J Controlled Release ,2000,69(3 ) :379.
